Immediate Impact
1 standout
Citing Papers
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
Works of Sandrine Bernhard being referenced
Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.
2023
Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.
2023
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Sandrine Bernhard | 24 | 19 | 2 | 4 | 25 | ||
| Alba Zarate | 28 | 29 | 1 | 2 | 5 | 31 | |
| Zakhi Zafrani | 26 | 17 | 2 | 26 | |||
| Giovanni Spiezio | 22 | 20 | 4 | 3 | 30 | ||
| Ajit Dhillon | 20 | 12 | 1 | 4 | 5 | 22 | |
| Nicolas Flamey | 16 | 17 | 2 | 18 | |||
| Hans Biberstein | 20 | 12 | 6 | 3 | 25 | ||
| Fennie Wit | 19 | 12 | 1 | 5 | 24 | ||
| Vanesa Catalán | 33 | 9 | 2 | 5 | 34 | ||
| Suzanne Doré | 13 | 12 | 3 | 5 | 20 | ||
| Giacomo Bertelli | 15 | 12 | 5 | 3 | 4 | 22 |
All Works
Login with ORCID to disown or claim papers
Loading papers...